Bipolar Hormone Therapy, BAT for Prostate Cancer, BAT Patient Guide
Cancer ABCs
Bipolar Androgen Therapy (BAT): A Patient's ...

This complete guide to Bipolar Androgen Therapy (BAT) should be your stepping-off point if you are interested in using BAT to treat your castrate-resistant prostate cancer (CrPC).

Bipolar Androgen Therapy (BAT): A Patient's Guide
Radiopharmaceutical Treat
Cancer ABCs
Which is Better, 177Lu-PSMA-617 (Pluvicto) or ...

Several men have asked us if they are better off having 177Lu-PSMA-617 (Pluvicto) or Xofigo, a radiopharmaceutical drug that treats bone metastases. There is no simple answer, and the answer is not the same for each of us. Making a sound decision can be helped by understanding the mode of action and the limits of each treatment.

Which is Better, 177Lu-PSMA-617 (Pluvicto) or Xofigo (Radium-223)
PARP Inhibitors, Companion Diagnostics, BRACA
Cancer ABCs
Understanding the PARP Inhibitors - Who Will ...

LYNPARZA (olaparib) and RUBRACA (rucaparib) are PARP Inhibitors that were FDA approved in May of 2020 for men with castrate resistant prostate cancer who also have certain genetic mutations. The FDA also approved certain Companion Diagnostic genetic tests to go along with the decision making to use these PARP Inhibitors.

There is a lot of information now available with these recent developments which makes decision making confusing.

Understanding the PARP Inhibitors - Who Will Benefit?
Radiation Side Effect Man, Managing Radiation Side
Cancer ABCs
Managing Late Stage Radiation Side Effects

There are several possible side effects that can result from receiving radiation treatment. The most common of these side effects include the development of scar tissue that makes it hard to urinate (pee), defecate (poop), and in some instances, link the activity of either peeing and pooping together; bladder or colon bleeding and diarrhea. 

Managing Late Stage Radiation Side Effects

Zytiga

,

Apalutamide plus Zytiga and prednisone Delays Progression of Metastatic Castration-Resistant Prostate Cancer.

,
Apalutamide plus Zytiga and prednisone Delays Progression of Metastatic Castration-Resistant Prostate Cancer.

The combination of Zytiga (abiraterone), prednisone, and Erleada (apalutamide) can delay the progression of metastatic castrate-resistant prostate cancer.

, ,

Optimal Chemo-Hormonal Sequencing for mCRPC Maybe Taxotere – Zytiga – Jevtana – Xtandi 

, ,
Optimal Chemo-Hormonal Sequencing for mCRPC Maybe Taxotere – Zytiga – Jevtana – Xtandi 

Optimal Chemo-Hormonal Sequencing for metastatic castrate resistant prostate cancer (mCRPC) maybe Taxotere – Zytiga – Jevtana – Xtandi

,

Is ADT Necessary When You Take Abiraterone Acetate (Zytiga)?

,
Is ADT Necessary When You Take Abiraterone Acetate (Zytiga)?

The researchers concluded that ADT might not be necessary for men receiving Zytiga and prednisone. However, some men may experience a rapid increase in serum testosterone levels, which warrants close monitoring and adding back ADT.

,

Is ADT Necessary When You Take Abiraterone Acetate (Zytiga)?

,
Is ADT Necessary When You Take Abiraterone Acetate (Zytiga)?

The researchers concluded that ADT may not be necessary for men receiving Zytiga and prednisone; however, some men may experience a rapid increase of serum testosterone levels, warranting close monitoring and adding back ADT.

, ,

Statins, Vitamin D and Zytiga

, ,
Statins, Vitamin D and Zytiga

A post hoc analysis of two randomized clinical trials shows some evidence that taking statins and vitamin D supplements might reduce the risk of death in men who have castrate resistant prostate cancer (CRPC) who are also taking the drug Zytiga (abiraterone acetate or AA) with prednisone.

,

Statins and Vitamin D Might Reduce the Risk of Death in Men with Castrate Resistant Prostate Cancer Taking Zytiga 

,
Statins and Vitamin D Might Reduce the Risk of Death in Men with Castrate Resistant Prostate Cancer Taking Zytiga 

In this data analysis from two prospective randomized clinical trials, statin and vitamin D use was associated with superior overall survival in men with metastatic CRPC who were treated with Zytiga and prednisone.

,

Lower Doses of Zytiga with Food

,

There was a small clinical trial, by Mark Ratain, M.D., of the University of Chicago, that suggests that it is possible to take a lower dose of Zytiga (abiraterone) along with a low-fat breakfast and achieve a response similar to the one we would expect to see with a full dose on an empty stomach.  

, , , ,

Update on the Combination Use of Zytiga and Xofigo

, , , ,

Sub-group analysis of the clinical trial ERA 223 signal that the concerns about the use in combination of Zytiga and Xofigo might not cause a significant increase in the risk for developing bone fractures if a man is also simultaneously on a bone targeted therapy.

,

The Synergy between Xtandi and Zytiga with ADT – Is it Important to Continue Taking ADT Along with Xtandi and Zytiga?

,

Why are Zytiga and Xtandi added to ADT and not substituted for ADT? Do I really need to continue ADT when I use Xtandi or Zytiga?

, ,

Can You Use Low Dose Zytiga with Food?

, ,

The standard dose of abiraterone acetate (Zytiga) is 1,000 mg. taken on an empty stomach, however, when just 250 mgs are taken with food, it seems that for many men this lower dosage has the same activity as Zytiga at 1,000 mg without food. 

, , , ,

Lynparza with Zytiga Improves Outcomes

, , , ,

Recently presented data has shown that there is a clinical improvement in median radiologic progression-free survival (rPFS) when olaparib (Lynparza) is used in combination with abiraterone (ZYTIGA) compared to abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC). 

,

AR-V7 Liquid Biopsy Coming of Age

,

Once a man is castrate resistant and moves on a second line hormone therapy drug like Zytiga or Xtandi (aka AR inhibitors) it is inevitable that the Zytiga or Xtandi will also become ineffective.  

When this happens, the question that comes is what should be the next treatment?  Generally, the options currently available are either to move to the drug not initially used ( Zytiga if Xtandi was first used or Xtandi if Zytiga was used) or instead to use taxane chemotherapy (Taxotere aka docetaxel).  

Abiraterone or Docetaxel? 

Since the approvals for the early use of docetaxel chemotherapy (Taxotere) and the early use of abiraterone acetate (Zytiga) there is no clear evidence demonstrating which of these two agents should be used for men with hormone sensitive, newly diagnosed, aggressive prostate cancer. 

,

A Generic Version of Zytiga Has Been Approved by the FDA

,

The U.S. Food and Drug Administration (FDA) has approved a generic version of Zytiga, the new drug’s name is Yonsa.  It is a novel formulation of abiraterone acetate that needs to be used in combination with methylprednisolone for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).

,

Statin Use Along with Zytiga or Xtandi Extends Survival in Men Who Failed Chemotherapy 

,

Statins have been in the prostate cancer news feeds for a long time.  They are believed to potentiate the effects of the anti-hormonal agents used to treat metastatic castration-resistant prostate cancer (mCRPC). Different stages of prostate cancer as well as different treatment exposures might change the efficacy of statins. 

, ,

Warning - A Possible Danger - Xofigo in Combination with Zytiga and Prednisone

, ,

The European Medicines Agency (EMA) has recommended halting the use of the Xofigo (radium-223 dichloride) in combination with Zytiga (abiraterone acetate) and prednisone due to a possible increased risk of death and fractures.

, ,

Choosing Docetaxel or Zytiga

, ,

Both Taxotere (docetaxel) and Zytiga (abiraterone) are approved for newly diagnosed men with very aggressive prostate cancer and who have not yet had any exposure to hormone therapy (ADT).  

The two approvals lead us to the question, which of these treatment options would be best for you? 

Gold Guidestar Seal
Gold Transparency 2022